Indaptus Therapeutics, Inc.
INDP
$2.16
$0.168.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.77% | -16.77% | -11.83% | -7.33% | -2.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.09% | -0.83% | 0.81% | -6.18% | -5.60% |
| Operating Income | -3.09% | 0.83% | -0.81% | 6.18% | 5.60% |
| Income Before Tax | -13.25% | -7.71% | -5.15% | 2.60% | 1.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.25% | -7.71% | -5.15% | 2.60% | 1.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.25% | -7.71% | -5.15% | 2.60% | 1.21% |
| EBIT | -3.09% | 0.83% | -0.81% | 6.18% | 5.60% |
| EBITDA | -3.10% | 0.83% | -0.82% | 6.18% | 5.60% |
| EPS Basic | 34.25% | 27.74% | 16.19% | 11.67% | 4.51% |
| Normalized Basic EPS | 34.25% | 27.74% | 16.19% | 11.67% | 4.51% |
| EPS Diluted | 34.25% | 27.74% | 16.19% | 11.67% | 4.51% |
| Normalized Diluted EPS | 34.25% | 27.74% | 16.19% | 11.67% | 4.51% |
| Average Basic Shares Outstanding | 97.85% | 49.88% | 28.06% | 11.38% | 4.25% |
| Average Diluted Shares Outstanding | 97.85% | 49.88% | 28.06% | 11.38% | 4.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |